Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

Conclusions
DCV+SOF with or without RBV achieved high SVR12 and was well tolerated in a diverse cohort of patients with severe liver disease.

Trial registration number
NCT0209966.

Source: Gut - October 6, 2016 Category: Gastroenterology Authors: Welzel, T. M., Petersen, J., Herzer, K., Ferenci, P., Gschwantler, M., Wedemeyer, H., Berg, T., Spengler, U., Weiland, O., van der Valk, M., Rockstroh, J., Peck-Radosavljevic, M., Zhao, Y., Jimenez-Exposito, M. J., Zeuzem, S. Tags: Open access Hepatology Source Type: research